Chris Schott
Stock Analyst at J.P. Morgan
(4.06)
# 1,597
Out of 4,386 analysts
631
Total ratings
56%
Success rate
4.6%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintained: Hold | $30 | $25.62 | +17.10% | 87 | Jun 1, 2026 | |
| REGN Regeneron Pharmaceuticals | Rated: Buy | $950 → $850 | $611.34 | +39.04% | 31 | May 18, 2026 | |
| VTRS Viatris | Rated: Hold | $17 → $18 | $15.93 | +12.99% | 27 | May 8, 2026 | |
| ZTS Zoetis | Rated: Buy | $190 → $130 | $78.82 | +64.93% | 15 | May 8, 2026 | |
| ELAN Elanco Animal Health | Rated: Buy | $28 → $30 | $23.68 | +26.69% | 21 | May 7, 2026 | |
| RPRX Royalty Pharma | Maintained: Buy | $50 → $58 | $54.86 | +5.72% | 9 | May 7, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | $35 → $40 | $33.26 | +20.26% | 42 | Apr 30, 2026 | |
| BIIB Biogen | Maintained: Hold | $175 → $185 | $192.62 | -3.96% | 18 | Apr 24, 2026 | |
| JNJ Johnson & Johnson | Maintained: Hold | $250 → $260 | $232.16 | +11.99% | 18 | Apr 15, 2026 | |
| ABBV AbbVie | Maintained: Buy | $260 | $223.07 | +16.56% | 36 | Apr 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 → $135 | $119.52 | +12.95% | 33 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,300 | $1,149.15 | +13.13% | 69 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $13.71 | +31.29% | 19 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 → $15 | $11.61 | +29.20% | 31 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $128.10 | - | 31 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $12 → $11 | $13.39 | -17.85% | 13 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 | $55.57 | +16.97% | 40 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $675 → $775 | $561.17 | +38.10% | 15 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $300 | $345.73 | -13.23% | 11 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $9 → $8 | $1.42 | n/a | 9 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.16 | n/a | 41 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.88 | n/a | 3 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €83.29 → €85.02 | $137.45 | n/a | 2 | Mar 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $43 → $54 | $22.86 | n/a | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $2.29 | n/a | 3 | Nov 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $14.20 | n/a | 1 | Oct 17, 2013 |
Pfizer
Jun 1, 2026
Maintained: Hold
Price Target: $30
Current: $25.62
Upside: +17.10%
Regeneron Pharmaceuticals
May 18, 2026
Rated: Buy
Price Target: $950 → $850
Current: $611.34
Upside: +39.04%
Viatris
May 8, 2026
Rated: Hold
Price Target: $17 → $18
Current: $15.93
Upside: +12.99%
Zoetis
May 8, 2026
Rated: Buy
Price Target: $190 → $130
Current: $78.82
Upside: +64.93%
Elanco Animal Health
May 7, 2026
Rated: Buy
Price Target: $28 → $30
Current: $23.68
Upside: +26.69%
Royalty Pharma
May 7, 2026
Maintained: Buy
Price Target: $50 → $58
Current: $54.86
Upside: +5.72%
Teva Pharmaceutical Industries
Apr 30, 2026
Maintained: Buy
Price Target: $35 → $40
Current: $33.26
Upside: +20.26%
Biogen
Apr 24, 2026
Maintained: Hold
Price Target: $175 → $185
Current: $192.62
Upside: -3.96%
Johnson & Johnson
Apr 15, 2026
Maintained: Hold
Price Target: $250 → $260
Current: $232.16
Upside: +11.99%
AbbVie
Apr 7, 2026
Maintained: Buy
Price Target: $260
Current: $223.07
Upside: +16.56%
Apr 6, 2026
Maintained: Buy
Price Target: $125 → $135
Current: $119.52
Upside: +12.95%
Apr 2, 2026
Reiterated: Buy
Price Target: $1,300
Current: $1,149.15
Upside: +13.13%
Mar 2, 2026
Maintained: Buy
Price Target: $18
Current: $13.71
Upside: +31.29%
Feb 27, 2026
Maintained: Hold
Price Target: $18 → $15
Current: $11.61
Upside: +29.20%
Feb 23, 2026
Maintained: Buy
Price Target: n/a
Current: $128.10
Upside: -
Feb 13, 2026
Maintained: Sell
Price Target: $12 → $11
Current: $13.39
Upside: -17.85%
Jan 28, 2026
Maintained: Buy
Price Target: $65
Current: $55.57
Upside: +16.97%
Nov 3, 2025
Maintained: Buy
Price Target: $675 → $775
Current: $561.17
Upside: +38.10%
Sep 16, 2025
Maintained: Hold
Price Target: $300
Current: $345.73
Upside: -13.23%
May 25, 2023
Maintained: Hold
Price Target: $9 → $8
Current: $1.42
Upside: n/a
Jul 28, 2022
Downgraded: Hold
Price Target: n/a
Current: $7.16
Upside: n/a
May 19, 2020
Downgraded: Hold
Price Target: n/a
Current: $1.88
Upside: n/a
Mar 9, 2020
Maintained: Buy
Price Target: €83.29 → €85.02
Current: $137.45
Upside: n/a
Feb 20, 2020
Maintained: Hold
Price Target: $43 → $54
Current: $22.86
Upside: n/a
May 13, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Nov 17, 2017
Maintained: Buy
Price Target: $35
Current: $2.29
Upside: n/a
Oct 17, 2013
Downgraded: Hold
Price Target: n/a
Current: $14.20
Upside: n/a